**Abstract**

**Objectives:** We tested the applicability of a previously-developed paliperidone palmitate 3-month (PP3M) population pharmacokinetic (pop-PK) model to PK data from Chinese and Japanese patients from a global PP3M phase-3 study (NCT01515423). A pharmacokinetic/pharmacodynamic (PK/PD) model was developed to describe the relationship between time course of paliperidone plasma concentrations following PP3M administration and relapse rates, as well as relevant risk factors.

**Methods:** PK data from 1369 patients were used for external validation of a pop-PK model^1^ previously developed on data from phase-1 and phase-3 studies^2,3^. Relevant covariate effects were body mass index (BMI) on volume of distribution; creatinine clearance on renal clearance; injection site, sex, injection volume on absorption parameters. The PK/PD analysis dataset included 1002 patients who were randomized to receive PP1M or PP3M in the double-blind phase.

**Results:** The pop-PK model was successfully validated on the new PK data. No model refinement was needed to describe Chinese and Japanese PK data. PK/PD modeling showed that higher paliperidone exposure was associated with reduced relapse risk, with no major differences in relapse rates between PP1M and PP3M arms. Independently from paliperidone exposure, higher relapse hazard was identified for patients on concomitant benzodiazepine medication (+193% hazard; 95% confidence interval: 85--363%), and patients at Japanese centers (+129% hazard; 95% confidence interval: 36--283%).

**Conclusions:** The previously-developed pop-PK model and covariates adequately captured the PK of PP3M from the current study. Race did not influence PP3M pharmacokinetics after the impact of BMI was incorporated in the model. PK/PD modeling of relapse rates evidenced an exposure-response relationship, i.e. reduced risk of relapse for higher paliperidone concentrations. Concomitant benzodiazepine use (possibly to treat residual/emergent symptoms) may be interpreted as an indicator of higher patient severity, and hence higher risk of relapse. In model-based simulations, the PP1M and PP3M arms appeared to display similar relapse rates over time.
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